LON:VEC Vectura Group (VEC) Share Price, News & Analysis GBX 164.80 0.00 (0.00%) (As of 10/18/2021) Add Compare Share Share Today's Range 164.63▼ 16550-Day Range 164.80▼ 164.8052-Week Range 100▼ 176Volume203,761 shsAverage Volume3.37 million shsMarket Capitalization£1.01 billionP/E Ratio8.20Dividend Yield23.06%Price TargetN/A Stock AnalysisStock Analysis Get Vectura Group alerts: Email Address Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover About Vectura Group Stock (LON:VEC)Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.Read More VEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VEC Stock News HeadlinesSeptember 10, 2024 | finance.yahoo.comAptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler PlatformAugust 29, 2024 | finanznachrichten.deZengun Group AB: Zengun Group AB (publ) Interim Report January - June 2024September 16, 2024 | Capital Trends (Ad)More Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.August 20, 2024 | finanznachrichten.deAnora Group Oyj: Anora Group Plc's Half-year Report January-June 2024: Comparable EBITDA improved in Q2 due to higher gross marginAugust 12, 2024 | finance.yahoo.comACB Aug 2024 9.000 put (ACB240816P00009000)August 2, 2024 | uk.finance.yahoo.comQ2 2024 Ionis Pharmaceuticals Inc Earnings CallJuly 23, 2024 | uk.finance.yahoo.comPhilip Morris International Reports 2024 Second-Quarter and First-Half Results and Raises Full Year GuidanceMay 22, 2024 | dailymail.co.ukNasal spray to help impotenceSeptember 16, 2024 | Capital Trends (Ad)More Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukraine was used to cyberattacks. But the WhisperGate attack just before Russia's full-scale invasion was different. It was larger... and it was aimed at dismantling Ukraine's critical infrastructure. The company's unique expertise and scalable approach allowed them to nearly double revenues between 2021-2023, and they've added another $20 million in new sales orders this year alone. There is no denying - the opportunity here is massive.May 20, 2024 | finance.yahoo.comGlobal Nebulizer Market Forecast 2024-2030: Need for Devices Capable of Handling High-viscosity Medications in Cystic Fibrosis TreatmentsApril 16, 2024 | finance.yahoo.comWalmart chooses Swisslog ASRS powered by SynQ software to enhance transparency and delivery of quality products in third milk processing facilityFebruary 3, 2024 | finance.yahoo.comGlobal Smart Inhalers Market to Surpass 51.85 Billion by 2030 Driven by Increasing Prevalence of Chronic Respiratory DiseasesJanuary 16, 2024 | finance.yahoo.comPhilip Morris (PM) Poised Well on Pricing, Smoke-Free StrengthOctober 6, 2023 | lse.co.ukVEC.L Regulatory NewsSeptember 20, 2023 | msn.comPhilip Morris (NYSE:PM) Mulls Stake Sale in Pharma UnitSeptember 20, 2023 | msn.comTobacco Giant Philip Morris Rethinks Pharma Dive, Mulls Vectura Stake Sale Amid Challenges: ReportSeptember 20, 2023 | msn.comPhilip Morris evaluates selling stake in pharmaceuticals unit - reportSeptember 4, 2023 | washingtonpost.comNestle’s Lessons From Joining the Dud Deals ClubSee More Headlines Receive VEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vectura Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Major Sub-IndustryN/A Current SymbolLON:VEC CUSIPN/A CIKN/A Webwww.vectura.com Phone+44-1249-667700FaxN/AEmployees9,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio8.20 Forward P/E Ratio0.18 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.77 Current Ratio3.59 Quick Ratio3.20 Sales & Book Value Annual Sales£190.60 million Price / Sales5.31 Cash FlowGBX 13.20 per share Price / Cash Flow12.48 Book ValueGBX 91.70 per share Price / Book1.80Miscellaneous Outstanding Shares613,892,000Free FloatN/AMarket Cap£1.01 billion OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. William Downie (Age 54)CEO & Exec. Director Comp: $538.92kMr. Paul Andrew Fry (Age 54)CFO & Exec. Director Comp: $807kMr. Anthony FitzpatrickExec. VP of OperationsDr. Geraldine VenthoyeChief Scientific Officer & Exec. VP of Product Devel.Elizabeth KnowlesVP of Investor RelationsMr. John Murphy (Age 68)Gen. Counsel & Company Sec. David GinivanVP of Corp. CommunicationsMs. Christina OlsenExec. VP of Corp. Strategy & CommunicationsMs. Joanne Hombal (Age 47)Exec. VP of HR Mr. Roger Heerman (Age 48)Exec. VP of Commercial & Bus. Devel. More ExecutivesKey CompetitorsCathay International Holdings Limited (CTI.L)LON:CTISinclair PharmaLON:SPHMediclinic InternationalLON:MDCBTGLON:BTGAbcamLON:ABCView All Competitors VEC Stock Analysis - Frequently Asked Questions How have VEC shares performed this year? Vectura Group's stock was trading at GBX 164.80 at the start of the year. Since then, VEC stock has increased by 0.0% and is now trading at GBX 164.80. View the best growth stocks for 2024 here. How do I buy shares of Vectura Group? Shares of VEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Vectura Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vectura Group investors own include Hikma Pharmaceuticals (HIK), SEB (SKP), BTG (BTG), iRobot (IRBT), Sinclair Pharma (SPH), Sirius Minerals (SXX) and Coats Group (COA). This page (LON:VEC) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vectura Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vectura Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
